AMAG Financial Facts
Product sales, net: 115.78MLicense fee and other collaboration revenues: 40K
See Full Income Statement
Deferred revenues: 34.65M
Accumulated deficit: -289.59M
See Full Balance Sheet
AMAG Pharmaceuticals, Inc. (AMAG) Earnings
|
Expand Research on AMAG
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | -149.1% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +3.1% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8/6/20 |  |
Q220 | -$0.39 | -$0.19 | -$0.20 | $52.8M | $57.95M | = |  | | Details |
| 5/11/20 | |
Q120 | -$0.72 | N/A | N/A | $68.7M | $64.82M | = | | | Details |
| 3/4/20 | |
Q419 | -$5.89 | N/A | N/A | $89.7M | $88.1M | = | | | Details |
| 11/1/19 | |
Q319 | -$0.70 | -$0.66 | -$0.04 | $84.1M | $88.18M | = | | | Details |
| 8/7/19 | |
Q219 | -$3.57 | -$0.57 | -$3.00 | $78.1M | $91.77M | = | | | Details |
| 5/7/19 | |
Q119 | -$3.54 | N/A | N/A | $75.8M | $90.11M | = | | | Details |
| 2/7/19 | |
Q418 | -$0.64 | -$1.09 | +$0.45 | $88.1M | $98.92M | = | | | Details |
| 11/1/18 | |
Q318 | -$1.88 | -$0.57 | -$1.31 | $122.2M | $120.1M | = | | | Details |
